SCHEMBL27147404

SCHEMBL27147404

O=C(N1CC(NCc2ccc(C(F)(F)F)cc2Cl)C1)N1CC2(CC(c3cncc(F)c3)C2)C1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ FAAH O00519 1/20 0.37
▸ CRHR1 P34998 2/20 0.36
▸ P2RX7 Q99572 3/20 0.35
▸ MGLL Q99685 1/20 0.35
▸ PDCD1LG2 Q9BQ51 1/20 0.33
▸ CD274 Q9NZQ7 1/20 0.33
▸ ABHD6 Q9BV23 1/20 0.33
▸ PPARG P37231 2/20 0.32
▸ KCNH2 Q12809 1/20 0.32
▸ MCHR1 Q99705 1/20 0.32
▸ HDAC4 P56524 2/20 0.32
▸ EPHX2 P34913 1/20 0.32
▸ TRPA1 O75762 1/20 0.32
▸ CHRNA7 P36544 1/20 0.32
▸ LPL P06858 1/20 0.32
▸ LIPC P11150 1/20 0.32
▸ LIPG Q9Y5X9 1/20 0.32
▸ F2R P25116 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30012519 1.00 FAAH (0.37) FAAHCRHR1P2RX7MGLLPDCD1LG2
SCHEMBL30012574 0.85 FAAH (0.37) FAAHP2RX7MGLLPDCD1LG2CD274
SCHEMBL27146340 0.85 FAAH (0.37) FAAHP2RX7MGLLPDCD1LG2CD274
SCHEMBL25325226 0.82 FAAH (0.38) FAAHP2RX7MGLLPDCD1LG2CD274
SCHEMBL27147403 0.80 PDK2 (0.36) CRHR1MGLLABHD6MCHR1HDAC4
SCHEMBL30013207 0.76 MGLL (0.49) FAAHP2RX7MGLLABHD6HDAC4
SCHEMBL27150619 0.76 MGLL (0.49) FAAHP2RX7MGLLABHD6HDAC4
SCHEMBL25324075 0.75 P2RX7 (0.37) CRHR1P2RX7MGLLPDCD1LG2CD274
SCHEMBL25325835 0.74 MGLL (0.37) MGLLMCHR1
SCHEMBL30013062 0.74 CCR2 (0.35) PDCD1LG2CD274KCNH2TRPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240199587-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2024-06-20 — — US claimed
EP-4326714-A1 HETEROCYCLIC COMPOUNDS F. Hoffmann-La Roche AG (CH) 2024-02-28 — — EP claimed
US-20240199587-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2024-06-20 — — US disclosed
EP-4326714-A1 HETEROCYCLIC COMPOUNDS F. Hoffmann-La Roche AG (CH) 2024-02-28 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240199587-A1 HETEROCYCLIC COMPOUNDS CYP1B1, CYP1A1, CYP4B1 FAAH 1280/4885CRHR1 1277/4885P2RX7 81/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback